Amycretin

Overview

Amycretin is an investigational peptide being developed as a potential treatment for obesity and related metabolic conditions. It is designed as a single, unimolecular agent that activates two different biological pathways at once: the GLP-1 receptor and the amylin receptor system. By combining these two appetite-related mechanisms in one molecule, developers hope to achieve greater effects on appetite and body weight than targeting either pathway alone.

One notable feature of amycretin is that it has been studied in more than one form, including both an oral version and an injectable version. Oral delivery of peptides is technically challenging, so an orally available candidate in this class attracts particular interest.

It is important to emphasize that amycretin is experimental. It has not been approved by regulators for any use, and its profile is still being defined through clinical research. Any statements about its potential remain provisional until larger, longer studies are completed.

How it works

Amycretin is described as a dual agonist, meaning it stimulates two receptor systems with a single molecule. The first is the GLP-1 receptor, the same target engaged by widely studied incretin-based therapies, which influences appetite, satiety, and insulin-related signaling. The second is the amylin pathway; amylin is a hormone co-released with insulin that contributes to feelings of fullness and slowing of gastric emptying.

The rationale for combining these targets is that GLP-1 and amylin signaling may act through complementary routes in the brain and gut to reduce food intake. Engaging both simultaneously could, in theory, produce stronger or more durable effects on appetite regulation than a single mechanism.

Because amycretin is a peptide, its design must address stability and, in the oral form, absorption across the gut lining. The exact pharmacological details continue to be characterized in ongoing studies, and the relative contribution of each pathway in humans is still being clarified.

Research & evidence

Amycretin has been evaluated in early-phase clinical research exploring both its oral and injectable forms. Reported early results have been described as encouraging with respect to effects on body weight, which has generated considerable scientific and public interest in this dual-agonist approach.

However, early-phase trials are designed primarily to assess safety, tolerability, and preliminary signals rather than to establish definitive efficacy. The number of participants and the duration of follow-up at this stage are limited, so conclusions must remain cautious. Larger and longer randomized controlled trials are needed to confirm whether the early promise translates into meaningful, durable, and safe benefits.

This encyclopedia intentionally avoids citing specific numerical results, percentages, or trial dates, because such figures evolve as new data emerge and can be misleading when taken out of context. The honest summary is that amycretin shows early potential in an active and fast-moving area of metabolic research, with confirmation still pending.

Safety & legal status

As an investigational agent, amycretin's full safety profile has not yet been established. In the broader class of GLP-1 and amylin-related therapies, gastrointestinal effects such as nausea, vomiting, and reduced appetite are commonly observed, and it is reasonable to expect that tolerability will be a key focus of amycretin's ongoing evaluation. Only completed, peer-reviewed trials can define its specific risks.

Amycretin is not approved by any major regulatory authority for the treatment of obesity, diabetes, or any other condition. It is available only within the context of authorized clinical trials and is not a legally marketed medicine or a dietary supplement.

Products sold online claiming to be amycretin outside of formal clinical research should be treated with strong caution, as they are unregulated, unverified, and potentially unsafe. This encyclopedia does not provide dosing information, and decisions about participation in trials should be made only with qualified medical guidance.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Kuhre RE, Ballarín-González B, Brand CL, et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025. Peer-reviewed study
2. Fu L, Ding R, Xu G, et al. Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives. Metabolism. 2026. Peer-reviewed study
3. Khoo B, Tan TM. GLP-1 and amylin receptor multiagonism with amycretin for obesity management. Lancet. 2025. Peer-reviewed study
4. Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. Peer-reviewed study
5. Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet. 2025. Peer-reviewed study